In this issue, Genders et al. (2015) demonstrate in a cohort of organ transplant recipients that betapapillomavirus seropositivity around transplantation significantly increases the risk of developing keratinocyte carcinomas. These results further substantiate an etiologic role of betapapillomaviruses in skin cancer and raise prospects of anti-viral immunotherapy.
Immunosuppressed organ transplant recipients (OTRs) are at an increased risk of developing cancers with viral etiology, such as non-Hodgkin's lymphoma related to Epstein-Barr virus, Kaposi's sarcoma caused by human herpesvirus 8, and various anogenital and oral cancers induced by high-risk alphapapillomaviruses (Vajdic et al., 2006) . Especially striking is the high prevalence of keratinocyte carcinomas (KC), mainly due to the 4100-fold increased incidence of cutaneous squamous cell carcinoma (SCC). This results in a reversal of the general SCC to basal cell carcinoma (BCC) ratio in Caucasians and a dominance of SCC (Euvrard et al., 2003) . The highly increased risk of SCC in immunosuppressed patients points to a viral etiology in analogy with the characteristics of other virus-induced tumors. Papillomaviruses from genus beta have been regarded as likely candidates for a long time because of their widely accepted association with cutaneous SCC in patients with epidermodysplasia verruciformis (Pfister, 2003) . However, in spite of intriguing oncogenic and antiapoptotic activities of betapapillomaviruses (betaPVs), their significance in skin cancer remains disputed, mainly because of insufficient epidemiologic evidence. The retrospective follow-up study in this issue (Genders et al., 2015) provides new supportive evidence that betaPV do have a role in skin carcinogenesis. It shows that betaPV seropositivity around transplantation implies a significant risk of developing keratinocyte-derived malignancy over the following 22 years. There were no associations with alpha-, gamma-, or nupapillomavirus seropositivities.
The natural history of betaPV infections-a nightmare for epidemiology An IARC Monograph Working Group in 2009 classified betaPV HPV5 and HPV8 as possibly carcinogenic in epidermodysplasia verruciformis, but it considered betaPV overall as not classifiable concerning skin carcinogenicity in general. This ''failure'' is not especially surprising in view of our current understanding that betaPV infects the skin of probably all people soon after birth as one element in a well-controlled commensal flora (Weissenborn et al., 2009 ). Studies of intrafamilial transmission have revealed a majority of frequently exchanged, transient infections and a minority of persistent types. The typically missing differentiation between transient and persistent infections has undoubtedly diluted the significance of epidemiologic case-control studies. More recently, investigators have tried to focus on the biologically more relevant betaPV infections, but the definition of ''biologically relevant infection'' remains a matter of debate.
Antibody responses to early transforming viral proteins have had limited investigation. Detectable antibodies to structural proteins (usually L1) are taken as indicators of previous infection, sufficient in activity and duration to evoke an immune response (reviewed in Genders et al., 2015) . Seropositivity reflects both past and ongoing HPV infection. To identify ongoing infections strong enough to evoke an immune response, Proby et al. (2011) examined the presence of HPV DNA in plucked eyebrow hairs. A positive association was found between SCC development and concordant DNA and serum antibody positivity for any betaPV type (odds ratio (OR) 1.6; confidence interval (CI) 1.1-2.5) and for HPV36 (OR 2.4; CI 1.0-5.4). patients and in the general population (Weissenborn et al., 2012) . A casecontrol study of OTR showed, indeed, that patients in the highest cumulative betaPV DNA load tertile are at a significantly higher risk of developing SCC compared with those in the lowest tertile. Type-specific risks were identified for high DNA loads of HPV8, 20, 36, and 38 (Neale et al., 2013) .
A breakthrough in prospective studies
A prospective pilot study in 2007 found no significant differences in betaPV seroprevalence in controls and incident SCC cases, when blood was taken 418 months before diagnosis (Casabonne et al., 2007) . This paper raised the question whether the increased seroprevalence in cases of SCC might be a consequence of tumor formation rather than evidence for causality. The idea of ''reverse causality'' became a long-standing opinion maker. More recent prospective seroepidemiologic studies (reviewed by Genders et al., 2015) provided limited new evidence and could not identify HPV type-specific risks.
The first prospective study in OTR (Genders et al., 2015) reports a timedependent adjusted hazard ratio of 2.8 (CI 1.3-6.4) for keratinocyte cancer development related to betaPV seropositivity, between 1 year before and 1 year after organ transplantation. The lack of an association with antibody responses to alphaPV, gammaPV, and nuPV is not unexpected. On the other hand, the association with muPV seropositivity is surprising, because this virus genus is so far not thought to be associated with KCs. It can be noted that the cumulative cancer incidence increases linearly after transplantation for betaPV seropositive OTR in contrast to a step-wise increase for seronegative OTR. This might result from new or reactivated betaPV infections in the years after transplantation. Without longitudinal data about seroconversion one is left with speculation, but if it were true the association between betaPV and KCs would become stronger.
As HPV type-specific risk prediction is rare in the skin cancer field, it is highly remarkable that HPV8, HPV20, and HPV75 turned out to be most relevant for the positive association between betaPV and all KCs and that HPV8, HPV20, and HPV76 were associated with SCC (Genders et al., 2015) .
The controversial association of HPV in general and betaPV in particular with BCC is discussed, as more recent studies have found no correlation (reviewed by Genders et al., 2015) . The current cohort study reports comparable hazard ratios for SCC and BCC development related to betaPV serostatus. In contrast to SCC, however, HPV15 was associated with the development of BCC. These data suggest that one should not forget about HPV and BCC completely.
Conclusion and outlook
Papers, such as the one by Genders et al. (2015) , are well suited to shed light on the relationship between betaPV and skin cancer. Rapidly increasing knowledge about the oncogenic activities of betaPV early proteins and possible carcinogenic mechanisms (partially reviewed in Genders et al., 2015) adds plausibility to the epidemiologic findings. Taken together, there is mounting evidence that betaPV have a role in skin carcinogenesis.
If confirmed, this mechanistic link may be exploited for SCC prevention by anti-viral agents. Proof of principle for prophylactic vaccination against skin tumors was recently provided in the model of betaPV HPV8 transgenic mice (Marcuzzi et al., 2014) Non-transgenic littermate Figure 1 . Skin tumor prevention by vaccination of HPV8 transgenic skin transplant recipients. The skin from transgenic mice expressing the early genome region of betapapillomavirus HPV8 in the basal layer of the epidermis was grafted onto non-transgenic littermates. The massive wounding rapidly induced papilloma growth in the transgenic skin. The non-transgenic recipient skin remained tumor free. Tumor growth in the transplant was prevented, when recipient mice had developed a measurable immune response after tattooing an HPV8-oncogene E6-DNA vaccine before transplantation (Marcuzzi et al., 2014). As vaccinated mice did not reject the HPV8-positive transplant, only those keratinocytes appear to be eliminated, as these express higher levels of E6 and would therefore give rise to papillomas. papilloma growth within 3 weeks. When transgenic mouse skin was transplanted to non-transgenic littermates, papillomas began to grow across the transplant surfaces (Figure 1) . In contrast, no papillomas developed when the recipient mice were immunized successfully with an HPV8-E6-DNA vaccine before transplantation. This is, at best, a long-term perspective for humans, but work in this area is worth every effort in view of the great skin cancer burden observed in allograft recipients who are immunosuppressed.
